Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes
about
Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumorsAn Update on the Effect of Incretin-Based Therapies on β-Cell Function and MassTreatment of prediabetesAssessment of pancreatic β-cell function: review of methods and clinical applicationsInterventions to preserve beta-cell function in the management and prevention of type 2 diabetesDulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetesEffects of GLP-1 on appetite and weightβ-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitusRestoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life spanPathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment.Postprandial serum C-peptide value is the optimal index to identify patients with non-obese type 2 diabetes who require multiple daily insulin injection: Analysis of C-peptide values before and after short-term intensive insulin therapy.GLP-1 receptor signalling promotes β-cell glucose metabolism via mTOR-dependent HIF-1α activationBariatric surgery and obesity: influence on the incretinsEffect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes.Profound defects in β-cell function in screen-detected type 2 diabetes are not improved with glucose-lowering treatment in the Early Diabetes Intervention Program (EDIP).Incretin-based therapies in prediabetes: Current evidence and future perspectivesExenatide's effect in reducing weight and glycosylated hemoglobin level in an Arab population with type 2 diabetesImportance of Beta Cell Function for the Treatment of Type 2 DiabetesEfficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind studyPotential use of exenatide for the treatment of obesity.Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitusCombination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature.Evolution of exenatide as a diabetes therapeutic.Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls.How do we continue treatment in patients with type 2 diabetes when therapeutic goals are not reached with oral antidiabetes agents and lifestyle? Incretin versus insulin treatmentPathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes.Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide.Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings.Obesity and appetite controlComing full circle in diabetes mellitus: from complications to initiation.Choice of early treatment regimen and impact on β-cell preservation in type 2 diabetes.The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy.What are the pharmacotherapy options for treating prediabetes?Implications of incretin-based therapies on cardiovascular disease.Combination immunotherapies for type 1 diabetes mellitus.
P2860
Q24598747-C5CBA530-E4CA-4F3A-9E0C-53B6DB4ABD05Q26749089-9B227766-F5AF-4CDA-8847-2B27FAAA1D0EQ26783350-9AD4ED47-D111-4A3D-B45E-E704886A0D45Q26829445-A55BC58B-DA35-454A-A5A1-123F9087B936Q26830871-ACBBD5ED-9C8B-406A-A2DD-90B6A57A6EE0Q26861768-3A858A19-43FF-4457-BB00-3ED996CD5EB8Q27011627-CF664012-5E68-4C3D-B569-87DAA2932403Q27692665-704CC0DC-054B-4916-991C-CD583D96766DQ28088578-EA00E823-51BC-42EB-8298-74D17595E7B3Q30572405-D7E2AA9B-4EBF-447C-80F4-E5667DB93DA9Q30597265-F9BCF2D4-94D6-403F-9701-602D2F360508Q33570085-339CEAD2-113A-4B24-809F-1BCB53FF2533Q33607770-1711E43B-6151-4DC1-9AF7-AD338D64F7C9Q33753096-94826FA3-F2B8-461D-B9D3-96905C4FBB42Q33838154-10DDA715-FB1C-40D1-8A5F-57D1A53AB132Q34073469-0965F4E0-81B3-4DEB-855C-DE04FBF14D45Q34498840-5762C2B4-54F3-434A-8A00-3E320ADC07BAQ34699191-B10ABB19-5AF8-42D7-B6AD-6E04D1501633Q35183579-65A3DEDA-5ED0-4661-A8EE-059F7BEC224CQ35667116-AAB6F0BA-D8CC-49A1-980D-6FB914719AECQ35688369-30B3DC4A-0D62-4A03-875E-57266CA4C9C4Q36391466-EA5FC7E0-1A1B-4517-894B-39CFA0E444C2Q36584204-F317D673-E035-495E-B6D8-8A5B0515B013Q36592820-3E220BE1-BF63-43DE-98E9-5F0BC3E02AC7Q36872178-5DA0C155-E124-4511-945D-9240EA215409Q36877205-5CD56EAD-483B-4452-AEF6-ADB29B628C4DQ37193295-2B1C1A3A-1215-4BCB-A908-5C4A302D574BQ37577129-1EB6C4DC-134E-496F-844A-2D6CCB8A171DQ37577162-CAA2B9F1-5A90-4442-9359-8F88D5CEA984Q37992259-0D849F02-0051-4625-8F8E-D5A58EFD654FQ38005223-C3AA2EA3-FA74-4001-8C13-8A7230B444F4Q38014516-A81346A7-44EE-4F8A-8AC8-9A2C3D55CFBFQ38035293-27BFC047-5595-40E6-8696-5542441D2459Q38072272-E0824E6A-06AB-4212-BF34-5359A5BC8F1EQ38129446-E5CF6ACB-8B56-47C3-B645-E51C9903FF4BQ38174279-D1DF0E3C-7CEE-4F36-AD30-1D0A0FA53B48Q38202156-893D1BE6-A4BC-4AB0-8B64-C6AD220D8424Q38241464-B03893F1-6E7F-49E0-803F-B035A082DA29Q38264374-C14019CA-A7B9-4447-886B-EA13323C2EE6Q38358009-845A4B20-F5D2-4E0B-AB64-1586FD025274
P2860
Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Effects of exenatide on measur ...... patients with type 2 diabetes
@ast
Effects of exenatide on measur ...... patients with type 2 diabetes
@en
type
label
Effects of exenatide on measur ...... patients with type 2 diabetes
@ast
Effects of exenatide on measur ...... patients with type 2 diabetes
@en
prefLabel
Effects of exenatide on measur ...... patients with type 2 diabetes
@ast
Effects of exenatide on measur ...... patients with type 2 diabetes
@en
P2093
P2860
P356
P1433
P1476
Effects of exenatide on measur ...... patients with type 2 diabetes
@en
P2093
Anja Cornér
Bjorn Eliasson
Marja-Riitta Taskinen
Mathijs C Bunck
Michaela Diamant
Rimma M Shaginian
P2860
P304
P356
10.2337/DC11-0291
P407
P577
2011-09-01T00:00:00Z